A phase 2 study analyzing safety and efficacy of SNP-630 in patients with Non-alcoholic-steatohepatitis
Latest Information Update: 08 Aug 2023
Price :
$35 *
At a glance
- Drugs SNP-630 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 08 Aug 2023 New trial record
- 24 Jun 2023 Results presented at the European Association for the Study of the Liver Congress 2023